RxDB
ICD-10-PCS Codes Browse (Tables)

ICD-10 PCS – Browse (Tables)

Code Title
– Top Categories
X New Technology
XW Anatomical Regions
XW0 Introduction New Technology, Anatomical Regions, Introduction
XW04 Central Vein
XW043 Percutaneous
XW0430 Brexanolone
XW04306 New Technology Group 6 Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6
XW0432 Nerinitide
XW04326 New Technology Group 6 Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
XW0433 Durvalumab Antineoplastic
XW04336 New Technology Group 6 Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW0435 Narsoplimab Monoclonal Antibody
XW04357 New Technology Group 7 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW0436 Lefamulin Anti-infective
XW04366 New Technology Group 6 Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW04367 New Technology Group 7 Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
XW0437 Coagulation Factor Xa, Inactivated
XW04372 New Technology Group 2 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
XW04377 New Technology Group 7 Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
XW0438 Lurbinectedin
XW04387 New Technology Group 7 Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
XW0439 Defibrotide Sodium Anticoagulant
XW04392 New Technology Group 2 Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2
XW04396 New Technology Group 6 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043A Bezlotoxumab Monoclonal Antibody
XW043A3 New Technology Group 3 Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 3
XW043A6 New Technology Group 6 Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043A7 New Technology Group 7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
XW043B Cytarabine and Daunorubicin Liposome Antineoplastic
XW043B3 New Technology Group 3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
XW043B6 New Technology Group 6 Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
XW043B7 New Technology Group 7 Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
XW043C Eculizumab
XW043C6 New Technology Group 6 Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
XW043C7 New Technology Group 7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043D Atezolizumab Antineoplastic
XW043D6 New Technology Group 6 Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
XW043E Remdesivir Anti-infective
XW043E5 New Technology Group 5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043E6 New Technology Group 6 Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043F Other New Technology Therapeutic Substance
XW043F3 New Technology Group 3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
XW043F5 New Technology Group 5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
XW043F6 New Technology Group 6 Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G Plazomicin Anti-infective
XW043G4 New Technology Group 4 Introduction of Plazomicin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 4
XW043G5 New Technology Group 5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043G6 New Technology Group 6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043G7 New Technology Group 7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043H Synthetic Human Angiotensin II
XW043H4 New Technology Group 4 Introduction of Synthetic Human Angiotensin II into Central Vein, Percutaneous Approach, New Technology Group 4
XW043H5 New Technology Group 5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H6 New Technology Group 6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
XW043H7 New Technology Group 7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043J Tisagenlecleucel Immunotherapy
XW043J7 New Technology Group 7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043K Fosfomycin Anti-infective
XW043K5 New Technology Group 5 Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043K7 New Technology Group 7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043L CD24Fc Immunomodulator
XW043L6 New Technology Group 6 Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
XW043L7 New Technology Group 7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043M Brexucabtagene Autoleucel Immunotherapy
XW043M7 New Technology Group 7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043N Meropenem-vaborbactam Anti-infective
XW043N5 New Technology Group 5 Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043N7 New Technology Group 7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
XW043Q Tagraxofusp-erzs Antineoplastic
XW043Q5 New Technology Group 5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043S Iobenguane I-131 Antineoplastic
XW043S5 New Technology Group 5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
XW043U Imipenem-cilastatin-relebactam Anti-infective
XW043U5 New Technology Group 5 Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043W Caplacizumab
XW043W5 New Technology Group 5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5